NASDAQ$RGEN

Repligen Corp · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Repligen's financial performance declined due to decreased COVID-related revenue and overall softness in AsiaPac, but was offset by strong performance in Chromatography and Proteins franchises.

Repligen reported a 12% decrease in revenue for Q1 2023, totaling $182.7 million compared to $206.4 million in Q1 2022. The company's gross margin was 55.2%, and net income was $28.8 million, a 39% decrease year-over-year. Despite the decline, Repligen is optimistic about long-term growth in bioprocessing, supported by strategic acquisitions and new product development.

  • First quarter revenue was reported at $182.7 million, with base business growth of 4% as reported and 7% at constant currency.
  • Gross margin for the first quarter was 55.2% on both GAAP and adjusted (non-GAAP) basis.
  • The acquisition of single-use bag manufacturer FlexBiosys Inc. was closed in April, expanding the fluid management portfolio.
  • The company saw strong performance from Chromatography and Proteins franchises, offset by a decline in Filtration revenue.

Headline financials

Total Revenue

$183M

Previous: $206M-11.5%
EPS (adj)

$0.64

Previous: $0.92-30.4%
Gross Margin

55.2%

Previous: 60.1%-8.2%
Capital Expenditures

-$8.51M

Previous: -$27.2M+68.7%
Free Cash Flow

$20.3M

Previous: $19.8M+2.8%
Net Income

$28.8M

Previous: $47M-38.6%
Operating Income

$31.3M

Previous: $60M-47.9%
Gross Profit

$101M

Previous: $124M-18.7%
Cash & Equivalents

$517M

Previous: $585M-11.6%
Total Assets

$2.54B

Previous: $2.38B+6.5%
Stock-Based Comp

$7.25M

Previous: $7.92M-8.4%

Revenue & EPS history

Repligen · Revenue · Quarterly

$183M

Q1 2023-11.5%vs Q1 2022
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Repligen · $183M total across 2 segments · Q1 2023

  • Product Revenue
    $183M-11.5%
  • Royalty and Other
    $39K+5.4%

Forward guidance

Repligen adjusted its full year 2023 financial guidance, expecting total revenue between $720 and $760 million, and base business growth of 4% to 8%.

Tailwinds

  • Total reported revenue is expected to be in the range of $720-$760 million.
  • COVID-related revenue is expected to be in the range of $30-$40 million.
  • Base business is expected to grow 4%-8% as reported and at constant currency.
  • Gross margin is expected to be 52%-53% on both a GAAP and non-GAAP basis.
  • Adjusted net income per share is expected to be in the range of $2.35-$2.42 on a fully diluted basis.

Headwinds

  • Total reported revenue guidance was adjusted down from $760-$800 million.
  • Base business growth expectation was adjusted down from 11%-15% as reported and 12%-16% at constant currency.
  • Gross margin guidance was adjusted down from 52.5%-53.5%.
  • Income from operations is expected to be in the range of $111-$116 million on a GAAP basis, compared to previous guidance of $135-$141 million.
  • Adjusted operating margin is expected to be in the range of 20.5%-21.5%, compared to previous guidance of 22.5%-23.5%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+2.6%

Avg return

Earnings day

+3.4%

Avg return

5 days after

+4.4%

Avg return

30 days after

59%

36 / 61 earnings

Positive

+22.1%

Q3 2018

Best reaction

-23.0%

Q3 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.1%-7.8%-2.7%
Q4 2025+1.4%-4.9%-15.5%
Q3 2025-5.9%-7.5%+6.3%
Q1 2025-2.9%-1.5%-14.8%
Q4 2024+7.9%+7.1%-7.1%
Q3 2024+7.9%-10.6%+11.8%
Q2 2024+21.3%+17.2%+9.2%
Q1 2024+1.3%+2.3%-9.2%
Q4 2023-3.2%-4.0%-0.9%
Q3 2023+15.1%+31.7%+37.7%
Q2 2023+1.1%+2.5%+5.2%
Q1 2023+6.4%+4.3%+8.8%
Q4 2022+3.2%-2.7%-10.0%
Q3 2022-6.0%-4.5%+3.1%
Q2 2022+13.1%+15.9%+0.6%
Q1 2022+7.8%+11.4%+19.3%
Q4 2021-1.8%-1.4%+4.0%
Q3 2021+7.2%+11.7%+5.5%
Q2 2021+14.2%+19.3%+32.4%
Q1 2021-6.4%-9.8%-15.6%
Q4 2020+0.3%+7.4%-11.1%
Q3 2020+8.1%+0.0%+0.8%
Q2 2020+8.7%+12.8%+8.2%
Q1 2020+6.7%+11.9%+5.0%
Q4 2019-10.1%-22.2%-18.7%
Q3 2019+9.9%+6.1%+15.1%
Q2 2019-4.0%-3.2%-1.7%
Q1 2019+2.5%-0.2%+11.5%
Q4 2018-0.2%+1.0%-0.2%
Q3 2018+22.1%+25.2%+19.3%
Q2 2018-1.0%+2.0%+14.2%
Q1 2018+5.1%+10.2%+14.9%
Q4 2017+9.2%+9.5%+6.2%
Q3 2017-7.1%-13.0%-4.9%
Q2 2017+1.3%+4.4%+6.1%
Q1 2017+5.2%+6.3%+11.7%
Q4 2016+6.3%+6.4%+13.6%
Q3 2016-4.1%-1.1%+10.0%
Q2 2016-0.6%-1.1%+3.9%
Q1 2016+2.1%
Q4 2015+2.4%
Q3 2015-23.0%
Q2 2015-0.2%
Q1 2015+16.9%
Q4 2014+14.9%
Q3 2014-6.6%
Q2 2014-3.6%
Q1 2014+5.0%
Q4 2013-8.8%
Q3 2013+8.8%
Q2 2013-0.1%
Q1 2013+2.9%
Q3 2010-5.0%
Q4 2012+5.8%
Q3 2012+10.2%
Q2 2012-0.4%
Q4 2010-1.5%
Q1 2012+0.9%
Q2 2011-0.1%
Q1 2011-0.9%
Q4 2011-0.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro